Codexis will report Q3 2025 financial results on November 6, followed by a conference call at 4:30 PM ET.
Quiver AI Summary
Codexis, Inc. announced it will release its financial results for the third quarter of 2025 on November 6, 2025, after market close. The company will hold a conference call and webcast at 4:30 pm Eastern Time to discuss these results and provide a business update, accessible via their Investor Relations website. The press release also highlights Codexis as a leader in enzymatic solutions for manufacturing complex therapeutics, utilizing its CodeEvolver® technology and developing the ECO Synthesis™ platform for RNAi therapeutics. These solutions aim to improve efficiency and sustainability in pharmaceutical manufacturing.
Potential Positives
- Codexis will report its financial results for Q3 2025 on November 6, indicating transparency and ongoing business activities.
- The conference call and webcast provide an opportunity for investors to engage directly with management, enhancing shareholder communication.
- The emphasis on Codexis' proprietary technology platforms, such as CodeEvolver® and ECO Synthesis™, highlights the company's commitment to innovation in therapeutic manufacturing.
- Codexis aims to drive significant improvements in manufacturing efficiencies and environmental sustainability, which positions the company favorably within the pharmaceutical industry.
Potential Negatives
- None
FAQ
When will Codexis report its Q3 2025 financial results?
Codexis will report its third quarter financial results on November 6, 2025, after market close.
What time is the Codexis financial conference call?
The conference call will take place at 4:30 PM Eastern Time on November 6, 2025.
How can I access the Codexis financial webcast?
The live webcast can be accessed on the Codexis Investor Relations website and will be archived for 90 days.
What are Codexis' key technological solutions?
Codexis specializes in enzymatic solutions for therapeutic manufacturing, utilizing its CodeEvolver® technology platform and ECO Synthesis™ platform.
Who can I contact for more information about Codexis?
For more information, you can contact Georgia Erbez, CFO of Codexis, at [email protected] or call (650) 421-8100.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CDXS Insider Trading Activity
$CDXS insiders have traded $CDXS stock on the open market 15 times in the past 6 months. Of those trades, 13 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CDXS stock by insiders over the last 6 months:
- MANAGEMENT INC. OPALEYE has made 13 purchases buying 2,915,000 shares for an estimated $6,928,186 and 0 sales.
- ALISON MOORE (Chief Technical Officer) sold 6,239 shares for an estimated $15,629
- GEORGIA ERBEZ (Chief Financial Officer) sold 6,239 shares for an estimated $15,628
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CDXS Hedge Fund Activity
We have seen 48 institutional investors add shares of $CDXS stock to their portfolio, and 60 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ABERDEEN GROUP PLC added 3,594,656 shares (+592.9%) to their portfolio in Q2 2025, for an estimated $8,770,960
- OPALEYE MANAGEMENT INC. added 3,100,000 shares (+32.6%) to their portfolio in Q2 2025, for an estimated $7,564,000
- NANTAHALA CAPITAL MANAGEMENT, LLC added 1,200,000 shares (+42.4%) to their portfolio in Q2 2025, for an estimated $2,928,000
- TELEMARK ASSET MANAGEMENT, LLC added 1,000,000 shares (+33.3%) to their portfolio in Q2 2025, for an estimated $2,440,000
- NUVEEN, LLC removed 947,411 shares (-75.9%) from their portfolio in Q2 2025, for an estimated $2,311,682
- CASDIN CAPITAL, LLC removed 900,000 shares (-11.1%) from their portfolio in Q2 2025, for an estimated $2,196,000
- CENTERBOOK PARTNERS LP removed 526,089 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,283,657
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
REDWOOD CITY, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the third quarter of 2025 on Thursday, November 6, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website , where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver
®
technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit
https://www.codexis.com
.
For More Information
Georgia Erbez
Chief Financial Officer
Codexis, Inc.
(650) 421-8100
[email protected]
